Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.23
+0.20 (2.49%)
At close: Apr 28, 2026, 4:00 PM EDT
8.20
-0.03 (-0.36%)
After-hours: Apr 28, 2026, 7:24 PM EDT
Emergent BioSolutions Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 742.9 | 1,044 | 1,049 | 1,118 | 1,774 | Upgrade
|
| Revenue Growth (YoY) | -28.81% | -0.54% | -6.10% | -36.99% | 12.45% | Upgrade
|
| Cost of Revenue | 375.6 | 732 | 795.1 | 827.4 | 980.4 | Upgrade
|
| Gross Profit | 367.3 | 311.6 | 254.2 | 290.1 | 793.2 | Upgrade
|
| Selling, General & Admin | 186.6 | 298.7 | 356.7 | 339.5 | 348.7 | Upgrade
|
| Amortization of Goodwill & Intangibles | 65.1 | 65.1 | 65.6 | 59.9 | 58.5 | Upgrade
|
| Operating Expenses | 251.7 | 363.8 | 422.3 | 399.4 | 407.2 | Upgrade
|
| Operating Income | 115.6 | -52.2 | -168.1 | -109.3 | 386 | Upgrade
|
| Interest Expense | -59.3 | -71 | -87.9 | -37.3 | -34.5 | Upgrade
|
| Other Non Operating Income (Expenses) | 54.2 | 11.9 | 6.4 | -11.7 | -3.7 | Upgrade
|
| EBT Excluding Unusual Items | 110.5 | -111.3 | -249.6 | -158.3 | 347.8 | Upgrade
|
| Merger & Restructuring Charges | -3.3 | -55.9 | -33.2 | -51.4 | - | Upgrade
|
| Impairment of Goodwill | - | - | -218.2 | -6.7 | -41.7 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 24.3 | 74.2 | - | - | Upgrade
|
| Asset Writedown | -12.2 | - | -306.7 | - | - | Upgrade
|
| Other Unusual Items | -12.2 | - | 2.3 | -2.6 | -2.9 | Upgrade
|
| Pretax Income | 82.8 | -142.9 | -731.2 | -219 | 303.2 | Upgrade
|
| Income Tax Expense | 30.2 | 47.7 | 29.3 | -7.4 | 83.7 | Upgrade
|
| Earnings From Continuing Operations | 52.6 | -190.6 | -760.5 | -211.6 | 219.5 | Upgrade
|
| Net Income | 52.6 | -190.6 | -760.5 | -211.6 | 219.5 | Upgrade
|
| Net Income to Common | 52.6 | -190.6 | -760.5 | -211.6 | 219.5 | Upgrade
|
| Net Income Growth | - | - | - | - | -28.22% | Upgrade
|
| Shares Outstanding (Basic) | 54 | 53 | 51 | 50 | 54 | Upgrade
|
| Shares Outstanding (Diluted) | 57 | 53 | 51 | 50 | 54 | Upgrade
|
| Shares Change (YoY) | 6.98% | 3.52% | 2.20% | -7.39% | 0.56% | Upgrade
|
| EPS (Basic) | 0.98 | -3.60 | -14.85 | -4.22 | 4.10 | Upgrade
|
| EPS (Diluted) | 0.93 | -3.60 | -14.85 | -4.22 | 4.06 | Upgrade
|
| EPS Growth | - | - | - | - | -28.52% | Upgrade
|
| Free Cash Flow | 156.8 | 35.8 | -257.9 | -149.9 | 96.1 | Upgrade
|
| Free Cash Flow Per Share | 2.77 | 0.68 | -5.04 | -2.99 | 1.78 | Upgrade
|
| Gross Margin | 49.44% | 29.86% | 24.23% | 25.96% | 44.72% | Upgrade
|
| Operating Margin | 15.56% | -5.00% | -16.02% | -9.78% | 21.76% | Upgrade
|
| Profit Margin | 7.08% | -18.26% | -72.48% | -18.93% | 12.38% | Upgrade
|
| Free Cash Flow Margin | 21.11% | 3.43% | -24.58% | -13.41% | 5.42% | Upgrade
|
| EBITDA | 208.9 | 53.4 | -47 | 15.7 | 504.2 | Upgrade
|
| EBITDA Margin | 28.12% | 5.12% | -4.48% | 1.41% | 28.43% | Upgrade
|
| D&A For EBITDA | 93.3 | 105.6 | 121.1 | 125 | 118.2 | Upgrade
|
| EBIT | 115.6 | -52.2 | -168.1 | -109.3 | 386 | Upgrade
|
| EBIT Margin | 15.56% | -5.00% | -16.02% | -9.78% | 21.76% | Upgrade
|
| Effective Tax Rate | 36.47% | - | - | - | 27.61% | Upgrade
|
| Revenue as Reported | 742.9 | 1,044 | 1,049 | 1,118 | 1,774 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.